in the U.S. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis was initiated in May 2025. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the...
autonomy for both Spain and the European Union. The Ministry provisionally awarded €53.2 million in funding on May 5, 2025, to support 37 breakthrough projects across 11 autonomous communities. INBRAIN’s project was one of several selected for...
immunoregulatory therapeutics for inflammatory and autoimmune diseases, will present at Digestive Disease Week 2025 first ever head-to-head clinical and translational results from two studies for omilancor, a Phase 3 first-in-class LANCL2 agonist...
comprises capabilities for low- to medium-volume DDC assembly and packaging. Both facilities will be GMP ready in fall 2025. In Europe, PCI recently acquired a packaging and device assembly facility in Dundalk, Ireland, which provides...
and the UK Government, including Innovate UK and the NIHR. The first participant was dosed in the trial on the 15th April 2025 and is expected to be completed in Q3 2025. Stablepharma’s next-generation technology platform StablevaX™ reformulates...
2b study in patients with moderate-to-severely active UC (XENITH-UC), with the expected study start in the second half of 2025. Lead selection for Xencor’s XmAb TL1A x IL23p19 bispecific antibody continues to advance. New in vitro studies show that...
more than 20 sites across the United States and Europe, with patient enrollment expected to begin in the fourth quarter of 2025. The trial’s primary endpoint, hepatic progression-free survival, is anticipated to be announced by the end of 2028,...
Association (AUA) Annual Meeting, the largest gathering of urologists in the world, which takes place April 26-29, 2025. "We know that healthcare providers value hands-on approaches to learning, and technology like the Spatial Computing Injection...
daily use per toe, making it an effortless addition to any self-care or health routine. What Makes BioClear Stand Out in 2025? The BioClear device is aligned with current health tech trends, combining smart wellness innovation with...
for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Beth will lead the commercial organization, including preparing for the U.S. launch of ENCELTOTM (revakinagene...
System to expand access to the limited supply of donor organs and improve post-transplant outcomes. As of April 2025, nearly 90,700 people are on the kidney transplant waiting list in the U.S., representing 86% of the national transplant list. In...
undergoing autologous stem cell transplant (ASCT; NCT05561751). Clinical trial results for this study are expected in Q4 2025. Current Evaluating Potential Indication Expansions – In addition to AML and MM, Exicure is evaluating a range of...
serious adverse outcomes in pregnant women with APS and their babies. The study results were published online on April 10, 2025 in Annals of the Rheumatic Diseases. “The IMPACT study represents a bold and very successful partnership over many years...
clinics in Australia. Pykus intends to submit an Investigational Device Exemption (IDE) application to the FDA in Q4 2025 for a multicenter U.S. pivotal trial, pending financing and regulatory discussions. The Company plans to meet with FDA in Q3...
Element Biosciences, a life sciences company democratizing access to advanced biological tools, is excited to announce the 2025 AVITI for Agrigenomics Accelerator Grant. This initiative seeks to advance research in plant and animal sciences by...
favorable pharmacokinetics and early signs of efficacy - SciTech is preparing to launch the SCLC trial in Q2/3 2025. The company anticipates that this trial will further validate the drug's broad therapeutic potential. "We are thrilled about the...
oral allergy medications like Benadryl®, making it a versatile, worry-free choice for families. Recognized as the 2025 Product of the Year in the Immediate Relief category, PBZ OTC is poised to become a staple in medicine cabinets nationwide. PBZ...
g/vial of Mylan Laboratories Limited, NDA 209481. According to IQVIA™ sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market2...
therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the AD/PD™ 2025. The results showed that Spectris™, the company’s non-invasive investigational neuromodulation device, maintains corpus...
equivalent to recombinant keratinocyte growth factor (KGF). This product will be on the market beginning April 2025. Development of Synthetic Peptide Growth Factors by PeptiGrowth: Conventional growth factors and cytokines used in the manufacturing...
